USTEKINUMAB

作品数：27被引量：41H指数：4
导出分析报告
相关领域：医药卫生更多>>
相关作者：杨惠芳王群季强于雪杨清锐更多>>
相关机构：南方医科大学广东省人民医院天津市儿童医院山东大学更多>>
相关期刊：《World Journal of Clinical Cases》《天津药学》《世界临床医学》《World Journal of Rheumatology》更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Clinical value of serum 25-hydroxyvitamin D level in predicting the efficacy of ustekinumab in the treatment of Crohn's disease with perianal fistula
《China Medical Abstracts(Internal Medicine)》2024年第4期218-219,共2页ZHANG Dingli 
Objective To evaluate the predictive value of serum 25-hydroxyvitamin D(25(OH)D)level for the clinical response and imaging response to anal fistula in patients with perianal fistulizing Crohn's disease(PFCD)treated w...
关键词：25(OH)D VITAMIN SERUM TREATMENT 
Refractory ulcerative colitis:Upadacitinib versus other biologics
《World Journal of Clinical Cases》2024年第31期6425-6427,共3页Said G Farhat Jessy G Fadel 
In this editorial we comment on an article published in World Journal of Clinical Cases in 2024,in which a case of refractory ulcerative colitis(UC)was discussed based on the response to different lines of biologics.D...
关键词：REFRACTORY Ulcerative colitis Upadacitinib USTEKINUMAB Vedolizumab 
Exit strategies in inflammatory bowel disease:Looking beyond antitumor necrosis factors被引量：1
《World Journal of Clinical Cases》2023年第12期2657-2669,共13页Federica Crispino Andrea Michielan Mauro Grova Chiara Tieppo Marta Mazza Teresa Marzia Rogger Franco Armelao 
The long-term management of patients with inflammatory bowel disease(IBD)is still a matter of debate,and no clear guidelines have been issued.In clinical practice,gastroenterologists often have to deal with patients i...
关键词：Exit strategy Biologic withdrawal Drug holiday Vedolizumab USTEKINUMAB Tofacitinib 
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease:a multicentre,randomised,double-blind,parallel-group,phase 3b trial被引量：14
《四川生理科学杂志》2022年第5期940-940,共1页Bruce E Sands 
Background:Active-comparator trials are important to inform patient and physician choice.We aimed to evaluate the efficacy and safety of monotherapy with either ustekinumab or adalimumab in biologic-naive patients wit...
关键词：PATIENTS centre moderately 
Ustekinumab Treatment in Patients with Moderate-to-Severe Psoriasis and Latent Tuberculosis Infection: A Study of 3 Case Reports
《Journal of Cosmetics, Dermatological Sciences and Applications》2022年第2期95-99,共5页Waqas S. Abdulwahhab Alaa S. Mehair Al Shayma F. Iedi 
Background: Ustekinumab is a human monoclonal antibody that binds to the shared P40 subunit of interleukin (IL)-12 and IL-23 and is approved for the treatment of moderate-to-severe psoriasis. Latent tuberculosis (LTBI...
关键词：PSORIASIS USTEKINUMAB Latent Tuberculosis QuantiFERON-TB Test 
Recalcitrant paradoxical pustular psoriasis induced by infliximab:Two case reports被引量：2
《World Journal of Clinical Cases》2021年第15期3655-3661,共7页Ping Xia Yan-Hong Li Zhong Liu Xu Zhang Qian Jiang Xiao-Yong Zhou Wei Su 
BACKGROUND Paradoxical psoriasis induced by tumor necrosis factor alpha antagonists is a rare side effect of those drugs and has similarities with and differences from classical psoriasis in clinical and pathological ...
关键词：Pustular psoriasis PARADOXICAL INFLIXIMAB Secukinumab USTEKINUMAB Antinuclear antibody Case report 
Approach to medical therapy in perianal Crohn’s disease被引量：6
《World Journal of Gastroenterology》2021年第25期3693-3704,共12页Abhinav Vasudevan David H Bruining Edward V Loftus Jr William Faubion Eric C Ehman Laura Raffals 
Perianal Crohn’s disease remains a challenging condition to treat and can have a substantial negative impact on quality of life.It often requires combined surgical and medical interventions.Anti-tumor necrosis factor...
关键词：FISTULA BIOLOGICS Inflammatory bowel disease SURGERY Stem cells INFLIXIMAB USTEKINUMAB 
First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases:A 2020 Delphi consensus被引量：2
《World Journal of Gastroenterology》2020年第43期6710-6769,共60页Maryam Alkhatry Ahmad Al-Rifai Vito Annese Filippos Georgopoulos Ahmad N Jazzar Ahmed M Khassouan Zaher Koutoubi Rahul Nathwani Mazen S Taha Jimmy K Limdi 
Supported by Emirates Gastroenterology and Hepatology Society,No.001802.
Ulcerative colitis and Crohn’s disease are the main entities of inflammatory bowel disease characterized by chronic remittent inflammation of the gastrointestinal tract.The incidence and prevalence are on the rise wo...
关键词：Ulcerative colitis Crohn’s disease INFLIXIMAB ADALIMUMAB Vedolizumab USTEKINUMAB Tofacitinib 
Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease
《World Journal of Gastroenterology》2019年第31期4481-4492,共12页Peter Hoffmann Johannes Krisam Cyrill Wehling Petra Kloeters-Plachky Yvonne Leopold Nina Belling Annika Gauss 
BACKGROUND Ustekinumab was approved in Europe for the treatment of adults with moderate to severe Crohn's disease(CD)in 2016,and there is an urgent need for data on its everyday use.AIM To obtain data on the daily use...
关键词：Eeal-world USTEKINUMAB Crohn’s DISEASE 
Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease被引量：4
《World Journal of Gastroenterology》2018年第36期4093-4103,共11页Ioanna Aggeletopoulou Stelios F Assimakopoulos Christos Konstantakis Christos Triantos 
Considering that both innate and adaptive immune responses are involved in the pathogenesis of Crohn's disease(CD), novel therapeutic options have significantly been developed. Biological agents represent an important...
关键词：Crohn’s disease INTERLEUKIN 12 INTERLEUKIN 23 MONOCLONAL ANTIBODIES USTEKINUMAB Biological agents INTERLEUKIN 12/interleukin 23 BLOCKADE 
全选清除导出
共3页<123>
检索报告 对象比较 聚类工具 使用帮助 返回顶部